8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Feb 26, 2026·SEC
BioCryst Pharmaceuticals, Inc.(BCRX)Earnings, Financials & Key Ratios
BCRX•NASDAQ
7.4× P/E·Price updated Jun 19, 2026
AboutBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Show more
- Revenue$875M+94.1%
- EBITDA$342M+26497.7%
- Net Income$264M+396.9%
- EPS (Diluted)1.21+381.4%
- Gross Margin97.82%+0.6%
- EBITDA Margin39.14%+13698.4%
- Operating Margin38.98%+7008.4%
- Net Margin30.16%+252.9%
BCRX Key Insights
BioCryst Pharmaceuticals, Inc. (BCRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 37.4% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 117.9%
- ✓Efficient asset utilization: 1.7x turnover
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BCRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCRX Price & Volume
BioCryst Pharmaceuticals, Inc. (BCRX) stock price & volume — 10-year historical chart
Loading chart...
BCRX Growth Metrics
BioCryst Pharmaceuticals, Inc. (BCRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years33.61%
5 Years117.89%
3 Years47.82%
TTM75.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-756.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-585.12%
Return on Capital
10 Years-52.75%
5 Years-0.57%
3 Years26.31%
Last Year105.22%
BCRX Recent Earnings
BioCryst Pharmaceuticals, Inc. (BCRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.03-150.0%
$0.06
Rev
$156M+3.5%
$151M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.12+1500.0%
$0.07
Rev
$407M+168.7%
$151M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$0.06-14.3%
$0.07
Rev
$159M+5.3%
$151M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.15+400.0%
$0.03
Rev
$163M+9.2%
$150M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.03vs $0.06-150.0% | $156Mvs $151M+3.5% |
| Q1 2026 | Feb 26, 2026 | $1.12vs $0.07+1500.0% | $407Mvs $151M+168.7% |
| Q4 2025 | Nov 3, 2025 | $0.06vs $0.07-14.3% | $159Mvs $151M+5.3% |
| Q3 2025 | Aug 4, 2025 | $0.15vs $0.03+400.0% | $163Mvs $150M+9.2% |
Based on last 12 quarters of dataView full earnings history →
BCRX Peer Comparison
BioCryst Pharmaceuticals, Inc. (BCRX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARGX | 54.32B | 877.72 | 44.71 | 89.64% | 32.14% | 24.93% | 0.01 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 |
Compare BCRX vs Peers
BioCryst Pharmaceuticals, Inc. (BCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCRX Income Statement
BioCryst Pharmaceuticals, Inc. (BCRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 25.19M | 20.65M | 48.84M | 17.81M | 157.17M | 270.83M | 331.41M | 450.71M | 874.84M | 885.72M |
Revenue Growth % | -4.43% | -18% | 136.45% | -63.53% | 782.38% | 72.31% | 22.37% | 36% | 94.1% | 75.92% |
Cost of Goods Sold | 1.7M | 471K | 4.1M | 1.68M | 7.26M | 6.59M | 4.66M | 12.48M | 19.07M | 718.37M |
COGS % of Revenue | 6.76% | 2.28% | 8.4% | 9.41% | 4.62% | 2.43% | 1.41% | 2.77% | 2.18% | - |
Gross Profit | 23.48M▲ 0% | 20.18M▼ 14.1% | 44.73M▲ 121.7% | 16.14M▼ 63.9% | 149.91M▲ 829.0% | 264.23M▲ 76.3% | 326.75M▲ 23.7% | 438.23M▲ 34.1% | 855.76M▲ 95.3% | 167.34M▲ 0% |
Gross Margin % | 93.24% | 97.72% | 91.6% | 90.59% | 95.38% | 97.57% | 98.59% | 97.23% | 97.82% | 18.89% |
Gross Profit Growth % | -0.72% | -14.06% | 121.65% | -63.93% | 829.02% | 76.27% | 23.66% | 34.12% | 95.28% | - |
Operating Expenses | 80.89M | 114.4M | 144.19M | 190.89M | 327.63M | 412.67M | 430.46M | 440.77M | 514.77M | 549.57M |
OpEx % of Revenue | 321.19% | 553.92% | 295.26% | 1071.71% | 208.45% | 152.37% | 129.89% | 97.79% | 58.84% | - |
Selling, General & Admin | 13.93M | 29.51M | 37.12M | 67.93M | 118.82M | 159.37M | 213.89M | 266.13M | 348.65M | 360.73M |
SG&A % of Revenue | 55.32% | 142.9% | 76.01% | 381.37% | 75.6% | 58.85% | 64.54% | 59.05% | 39.85% | - |
Research & Development | 66.96M | 84.89M | 107.07M | 122.96M | 208.81M | 253.3M | 216.57M | 174.64M | 166.13M | 189.18M |
R&D % of Revenue | 265.87% | 411.02% | 219.24% | 690.34% | 132.85% | 93.53% | 65.35% | 38.75% | 18.99% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -335K |
Operating Income | -57.41M▲ 0% | -94.22M▼ 64.1% | -99.45M▼ 5.6% | -174.76M▼ 75.7% | -177.72M▼ 1.7% | -148.44M▲ 16.5% | -103.71M▲ 30.1% | -2.54M▲ 97.5% | 340.99M▲ 13508.9% | -381.84M▲ 0% |
Operating Margin % | -227.95% | -456.2% | -203.66% | -981.12% | -113.07% | -54.81% | -31.29% | -0.56% | 38.98% | -43.11% |
Operating Income Growth % | -18.11% | -64.11% | -5.56% | -75.71% | -1.7% | 16.48% | 30.13% | 97.55% | 13508.93% | - |
EBITDA | -56.71M | -93.45M | -98.73M | -174.01M | -176.94M | -147M | -102.05M | -1.3M | 342.38M | -377.13M |
EBITDA Margin % | -225.15% | -452.48% | -202.17% | -976.92% | -112.58% | -54.28% | -30.79% | -0.29% | 39.14% | -42.58% |
EBITDA Growth % | -17.84% | -64.79% | -5.65% | -76.25% | -1.69% | 16.92% | 30.57% | 98.73% | 26497.69% | -1194.93% |
D&A (Non-Cash Add-back) | 704K | 770K | 724K | 748K | 777K | 1.44M | 1.66M | 1.25M | 1.39M | 4.71M |
EBIT | -57.22M | -92.08M | -97M | -168.31M | -122.52M | -145.29M | -117.99M | 11.56M | 346.26M | -379.59M |
Net Interest Income | -7.55M | -6.92M | -9.96M | -5.08M | -59.23M | -93.97M | -92.46M | -83.77M | -68.2M | -47.73M |
Interest Income | 1.01M | 2.25M | 1.93M | 9.42M | 62K | 5.13M | 15.78M | 14.75M | 10.67M | 9.9M |
Interest Expense | 8.56M | 9.18M | 11.89M | 14.5M | 59.29M | 99.09M | 108.24M | 98.52M | 78.87M | 35.6M |
Other Income/Expense | -8.37M | -7.03M | -9.44M | -8.06M | -4.09M | -95.95M | -122.52M | -84.41M | -73.6M | -72.34M |
Pretax Income | -65.78M▲ 0% | -101.25M▼ 53.9% | -108.9M▼ 7.6% | -182.81M▼ 67.9% | -181.81M▲ 0.5% | -244.38M▼ 34.4% | -226.23M▲ 7.4% | -86.95M▲ 61.6% | 267.39M▲ 407.5% | -454.18M▲ 0% |
Pretax Margin % | -261.18% | -490.25% | -222.99% | -1026.35% | -115.68% | -90.24% | -68.26% | -19.29% | 30.56% | -51.28% |
Income Tax | 0 | 0 | 0 | 0 | 2.25M | 2.73M | 310K | 1.93M | 3.53M | 3.81M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -1.24% | -1.12% | -0.14% | -2.22% | 1.32% | -0.84% |
Net Income | -65.78M▲ 0% | -101.25M▼ 53.9% | -108.9M▼ 7.6% | -182.81M▼ 67.9% | -184.06M▼ 0.7% | -247.12M▼ 34.3% | -226.54M▲ 8.3% | -88.88M▲ 60.8% | 263.86M▲ 396.9% | -457.98M▲ 0% |
Net Margin % | -261.18% | -490.25% | -222.99% | -1026.35% | -117.11% | -91.25% | -68.36% | -19.72% | 30.16% | -51.71% |
Net Income Growth % | -19.29% | -53.92% | -7.55% | -67.88% | -0.68% | -34.26% | 8.33% | 60.77% | 396.87% | -756.52% |
Net Income (Continuing) | -65.78M | -101.25M | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M | 263.86M | -457.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.78▲ 0% | -0.98▼ 25.6% | -0.94▲ 4.1% | -1.09▼ 16.0% | -1.03▲ 5.5% | -1.33▼ 29.1% | -1.18▲ 11.3% | -0.43▲ 63.6% | 1.21▲ 381.4% | -1.89▲ 0% |
EPS Growth % | -4% | -25.64% | 4.08% | -15.96% | 5.5% | -29.13% | 11.28% | 63.56% | 381.4% | -585.12% |
EPS (Basic) | -0.78 | -0.98 | -0.94 | -1.09 | -1.03 | -1.33 | -1.18 | -0.43 | 1.26 | - |
Diluted Shares Outstanding | 84.45M | 103.19M | 115.6M | 167.27M | 179.12M | 185.91M | 192.2M | 206.7M | 218.58M | 242.26M |
Basic Shares Outstanding | 84.45M | 103.19M | 115.6M | 167.27M | 179.12M | 185.91M | 192.2M | 206.7M | 209.89M | 242.26M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCRX Balance Sheet
BioCryst Pharmaceuticals, Inc. (BCRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 125.39M | 114.35M | 164.34M | 323.8M | 566.14M | 516.5M | 495.97M | 421.97M | 404.35M | 373.63M |
Cash & Short-Term Investments | 155.69M | 126.84M | 136.23M | 300.37M | 507.6M | 424.31M | 388.99M | 321.06M | 274.75M | 238.4M |
Cash Only | 50.28M | 26.73M | 114.17M | 272.13M | 504.39M | 304.77M | 110.64M | 104.92M | 89.74M | 171.59M |
Short-Term Investments | 64.11M | 77.74M | 22.05M | 28.24M | 3.21M | 119.54M | 278.34M | 216.14M | 185.01M | 66.81M |
Accounts Receivable | 6.12M | 4.29M | 22.15M | 8.65M | 29.41M | 50.6M | 56.95M | 79.07M | 106.82M | 0 |
Days Sales Outstanding | 88.65 | 75.87 | 165.52 | 177.17 | 68.31 | 68.19 | 62.72 | 64.03 | 44.57 | 29.81 |
Inventory | -37.8M | 1.65M | 0 | 7.04M | 15.79M | 27.53M | 28.68M | 8.09M | 5.4M | 5.99M |
Days Inventory Outstanding | - | 1.28K | - | 1.53K | 793.46 | 1.52K | 2.25K | 236.42 | 103.29 | 2.75 |
Other Current Assets | 3.5M | 1.54M | 1.55M | 2.22M | 3.35M | 14.06M | 21.35M | 13.75M | 17.38M | 129.24M |
Total Non-Current Assets | 52.87M | 32.49M | 10.94M | 10.91M | 22.02M | 33.5M | 20.99M | 68.45M | 109.81M | 91.43M |
Property, Plant & Equipment | 9.55M | 9.13M | 7.35M | 7.11M | 15.19M | 8.62M | 20.91M | 19.79M | 18.99M | 22.98M |
Fixed Asset Turnover | 2.64x | 2.26x | 6.65x | 2.50x | 10.35x | 31.43x | 15.85x | 22.78x | 46.08x | 43.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 41.3M | 22.38M | 0 | 0 | 6.83M | 18.08M | 0 | 21.72M | 61.16M | 131.5M |
Other Non-Current Assets | 2.03M | 978K | 3.59M | 3.8M | 0 | 6.81M | 80K | 26.94M | 29.66M | 47.87M |
Total Assets | 178.26M▲ 0% | 146.84M▼ 17.6% | 175.28M▲ 19.4% | 334.71M▲ 91.0% | 588.15M▲ 75.7% | 550M▼ 6.5% | 516.96M▼ 6.0% | 490.42M▼ 5.1% | 514.16M▲ 4.8% | 465.05M▲ 0% |
Asset Turnover | 0.14x | 0.14x | 0.28x | 0.05x | 0.27x | 0.49x | 0.64x | 0.92x | 1.70x | 1.88x |
Asset Growth % | 98.4% | -17.62% | 19.37% | 90.96% | 75.72% | -6.49% | -6.01% | -5.13% | 4.84% | -10.63% |
Total Current Liabilities | 74.84M | 69.48M | 92.33M | 105.65M | 103.72M | 105.51M | 149.99M | 160.38M | 196.07M | 195.39M |
Accounts Payable | 6.34M | 7.77M | 13.99M | 18.71M | 27.81M | 14.36M | 20.89M | 11.64M | 15.83M | 10.96M |
Days Payables Outstanding | 1.36K | 6.02K | 1.24K | 4.08K | 1.4K | 794.65 | 1.64K | 340.41 | 302.83 | 5.2 |
Short-Term Debt | 35.15M | 33.7M | 38.58M | 30M | 0 | 0 | 0 | 35.45M | 40.08M | 3.09M |
Deferred Revenue (Current) | 8.48M | 221K | 2.12M | 150K | 1.42M | 1.22M | 0 | 0 | 0 | 5.41M |
Other Current Liabilities | 21.89M | 23.08M | 6.19M | 44.58M | 52M | 36.46M | 86.59M | 64.66M | 140.16M | 175.93M |
Current Ratio | 1.68x | 1.65x | 1.78x | 3.06x | 5.46x | 4.90x | 3.31x | 2.63x | 2.06x | 1.91x |
Quick Ratio | 2.18x | 1.62x | 1.78x | 3.00x | 5.31x | 4.63x | 3.12x | 2.58x | 2.03x | 1.88x |
Cash Conversion Cycle | - | -4.67K | - | -2.37K | -535.52 | 797.58 | 672.75 | -39.96 | -154.97 | 27.36 |
Total Non-Current Liabilities | 19.66M | 28.13M | 44.7M | 248.32M | 591.42M | 739.08M | 822.5M | 805.97M | 437.25M | 823.5M |
Long-Term Debt | 16.75M | 25.37M | 41.29M | 244.45M | 585.46M | 733.28M | 811.26M | 795.92M | 427.23M | 12.29M |
Capital Lease Obligations | 2.75M | 2.7M | 3.41M | 3.87M | 5.96M | 5.8M | 11.23M | 10.05M | 10.01M | 30.71M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 155K | 54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 811.21M |
Total Liabilities | 94.49M | 97.61M | 137.03M | 353.98M | 695.14M | 844.6M | 972.49M | 966.35M | 633.31M | 1.02B |
Total Debt | 54.72M | 61.82M | 84.65M | 279.5M | 593.24M | 741.45M | 825.15M | 841.42M | 477.33M | 15.39M |
Net Debt | 4.44M | 35.09M | -29.52M | 7.38M | 88.85M | 436.69M | 714.5M | 736.5M | 387.59M | -156.2M |
Debt / Equity | - | - | 2.21x | - | - | - | - | - | - | -0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 1.39x | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.13x | 0.41x |
Interest Coverage | -6.68x | -10.03x | -8.16x | -11.61x | -2.07x | -1.47x | -1.09x | 0.12x | 4.39x | -10.66x |
Total Equity | -631.84M▲ 0% | -731.97M▼ 15.8% | 38.25M▲ 105.2% | -19.26M▼ 150.4% | -106.99M▼ 455.4% | -294.6M▼ 175.4% | -455.53M▼ 54.6% | -475.93M▼ 4.5% | -119.15M▲ 75.0% | -553.84M▲ 0% |
Equity Growth % | -11.62% | -15.85% | 105.23% | -150.36% | -455.43% | -175.36% | -54.63% | -4.48% | 74.96% | 80.99% |
Book Value per Share | -7.48 | -7.09 | 0.33 | -0.12 | -0.60 | -1.58 | -2.37 | -2.30 | -0.55 | -2.29 |
Total Shareholders' Equity | -631.84M | -731.97M | 38.25M | -19.26M | -106.99M | -294.6M | -455.53M | -475.93M | -119.15M | -553.84M |
Common Stock | 984K | 1.1M | 1.54M | 1.77M | 1.84M | 1.88M | 2.06M | 2.08M | 2.13M | 2.54M |
Retained Earnings | -631.84M | -731.97M | -840.63M | -1.02B | -1.21B | -1.45B | -1.68B | -1.77B | -1.51B | -2.23B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -243K | -297K | 39K | 3K | 177K | 26K | 1.34M | 921K | 38K | -368K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCRX Cash Flow Statement
BioCryst Pharmaceuticals, Inc. (BCRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -41.14M | -92.56M | -89.58M | -137.22M | -142.16M | -161.85M | -95.14M | -52.02M | 329.88M | 296.31M |
Operating CF Margin % | -163.36% | -448.19% | -183.44% | -770.36% | -90.45% | -59.76% | -28.71% | -11.54% | 37.71% | - |
Operating CF Growth % | 23.01% | -124.98% | 3.22% | -53.17% | -3.6% | -13.85% | 41.22% | 45.32% | 734.14% | 8787.11% |
Net Income | -65.78M | -101.25M | -108.9M | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M | 263.86M | -457.98M |
Depreciation & Amortization | 704K | 770K | 724K | 748K | 777K | 1.44M | 1.66M | 1.25M | 1.39M | 5.77M |
Stock-Based Compensation | 12.62M | 9.4M | 17.72M | 0 | 34.64M | 44.7M | 55.62M | 65.41M | 0 | 93.87M |
Deferred Taxes | 1.11M | 1.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 876K | 885K | 1.74M | 17.98M | -1.64M | 98.07M | 106.53M | 57.48M | 121.53M | 604.4M |
Working Capital Changes | 9.33M | -3.53M | -872K | 26.88M | 8.12M | -58.95M | -32.4M | -87.28M | -56.9M | -66.17M |
Change in Receivables | 2.65M | 568K | -17.85M | 13.9M | -20.82M | -21.47M | -6.09M | -22.7M | -36.81M | -23.29M |
Change in Inventory | 500K | -1.65M | 1.65M | -7.04M | -8.77M | -12.42M | -1.45M | -4.16M | -1.64M | -5.62M |
Change in Payables | 3.84M | 4.49M | 11.74M | 17.36M | 39.41M | -22.36M | -16.81M | -62.38M | 57.8M | 44.55M |
Cash from Investing | -66.38M | 4.77M | 77.93M | -6.86M | 15.8M | -128.24M | -131.5M | 52.59M | -13.69M | -309.44M |
Capital Expenditures | -328K | -366K | -343K | -514K | -2.38M | -1.35M | -2.17M | -1.12M | -2.47M | -2.73M |
CapEx % of Revenue | 1.3% | 1.77% | 0.7% | 2.89% | 1.52% | 0.5% | 0.65% | 0.25% | 0.28% | 0.31% |
Acquisitions | 12K | 366K | 0 | 0 | 0 | 0 | 0 | 0 | -6.18M | -495.66M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.74M | -366K | 0 | 1K | 0 | 0 | 0 | 0 | 550K | 550K |
Cash from Financing | 135.7M | 62.5M | 99.1M | 302.7M | 359.67M | 88.03M | 32.48M | -5.76M | -332.44M | 78.87M |
Debt Issued (Net) | 122K | 6.25M | 19.48M | 67.45M | 293.87M | 73.07M | 58.38M | -1.7M | -332.77M | 67.47M |
Equity Issued (Net) | 134M | 53.4M | 79.62M | 110.54M | 50.06M | 190K | 342K | 34K | 9.17M | 22.87M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.58M | 2.85M | 0 | 124.71M | 15.73M | 14.77M | -26.24M | -4.09M | -8.85M | -11.47M |
Net Change in Cash | 28.18M▲ 0% | -25.29M▼ 189.8% | 87.45M▲ 445.7% | 158.63M▲ 81.4% | 233.39M▲ 47.1% | -201.5M▼ 186.3% | -193.79M▲ 3.8% | -6.12M▲ 96.8% | -103.32M▼ 1587.2% | -21.37M▲ 0% |
Free Cash Flow | -41.47M▲ 0% | -92.93M▼ 124.1% | -89.93M▲ 3.2% | -137.73M▼ 53.2% | -144.54M▼ 4.9% | -163.2M▼ 12.9% | -97.31M▲ 40.4% | -53.14M▲ 45.4% | 327.41M▲ 716.1% | 293.58M▲ 0% |
FCF Margin % | -164.66% | -449.96% | -184.14% | -773.24% | -91.97% | -60.26% | -29.36% | -11.79% | 37.43% | 33.15% |
FCF Growth % | 29.37% | -124.09% | 3.23% | -53.16% | -4.95% | -12.91% | 40.37% | 45.39% | 716.08% | 1192% |
FCF per Share | -0.49 | -0.90 | -0.78 | -0.82 | -0.81 | -0.88 | -0.51 | -0.26 | 1.50 | 1.21 |
FCF Conversion (FCF/Net Income) | 0.63x | 0.91x | 0.82x | 0.75x | 0.77x | 0.65x | 0.42x | 0.59x | 1.25x | -0.64x |
Interest Paid | 0 | 0 | 0 | 0 | 900K | 0 | 22.14M | 30.38M | 0 | 7.53M |
Taxes Paid | 0 | 0 | 0 | 0 | 118K | 3.54M | 1.43M | 1.6M | 0 | 1.23M |
BCRX Key Ratios
BioCryst Pharmaceuticals, Inc. (BCRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -284.68% | -1925.37% | - | - | - | - | - | 123.57% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -179.63% | -38.79% | -0.73% | 96.69% | 3103.1% |
Gross Margin | 93.24% | 97.72% | 91.6% | 90.59% | 95.38% | 97.57% | 98.59% | 97.23% | 97.82% | 18.89% |
Net Margin | -261.18% | -490.25% | -222.99% | -1026.35% | -117.11% | -91.25% | -68.36% | -19.72% | 30.16% | -51.71% |
Debt / Equity | - | - | 2.21x | - | - | - | - | - | - | -0.03x |
Interest Coverage | -6.68x | -10.03x | -8.16x | -11.61x | -2.07x | -1.47x | -1.09x | 0.12x | 4.39x | -10.66x |
FCF Conversion | 0.63x | 0.91x | 0.82x | 0.75x | 0.77x | 0.65x | 0.42x | 0.59x | 1.25x | -0.64x |
Revenue Growth | -4.43% | -18% | 136.45% | -63.53% | 782.38% | 72.31% | 22.37% | 36% | 94.1% | 75.92% |
Related:BCRX Dividend History·BCRX Revenue History·BCRX Price History·BCRX P/E History·BCRX Financial Ratios·BCRX Institutional Holders
BCRX SEC Filings & Documents
BioCryst Pharmaceuticals, Inc. (BCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCRX Frequently Asked Questions
BioCryst Pharmaceuticals, Inc. (BCRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioCryst Pharmaceuticals, Inc. (BCRX) reported $885.7M in revenue for fiscal year 2025. This represents a 32704% increase from $2.7M in 1996.
BioCryst Pharmaceuticals, Inc. (BCRX) grew revenue by 94.1% over the past year. This is strong growth.
BioCryst Pharmaceuticals, Inc. (BCRX) reported a net loss of $458.0M for fiscal year 2025.
Dividend & Returns
BioCryst Pharmaceuticals, Inc. (BCRX) generated $293.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.